ReviewMedical oncology (Northwood, London, England)2017
Progress and challenges in the treatment of small cell lung cancer.
Review in Medical oncology (Northwood, London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 30 citations in OpenAlex.
- Current Surgical Perspective on the Prognosis of Small-Cell Lung Cancer.Diagnostics (Basel, Switzerland) · 2025Review
- Surgery is a promising strategy for improving overall survival for stage III-N2 non-small cell lung cancer patients.Journal of thoracic disease · 2023Article
- Non-canonical integrin signaling activates EGFR and RAS-MAPK-ERK signaling in small cell lung cancer.Theranostics · 2023Article
- Surgery and Surgery Approach Affect Survival of Patients With Stage I-IIA Small-Cell Lung Cancer: A Study Based SEER Database by Propensity Score Matching Analysis.Frontiers in surgery · 2022Article
- Use of cucurbitacins for lung cancer research and therapy.Cancer chemotherapy and pharmacology · 2021Review
- Chinese Medicine Treatment Prolonged Survival in Small Cell Lung Cancer Patients: A Clinical Observation.Chinese journal of integrative medicine · 2021Article
- Clinical Significance of CYFRA21-1, AFP, CA-153, CEA, and CA-199 in the Diagnosis of Lung Cancer Ocular Metastasis in Hypertension Population.Frontiers in cardiovascular medicine · 2021Article
- A narrative review of progress in diagnosis and treatment of small cell lung cancer patients with hyponatremia.Translational lung cancer research · 2020Review
- SOX2 mediates cisplatin resistance in small-cell lung cancer with downregulated expression of hsa-miR-340-5p.Molecular genetics & genomic medicine · 2020Article
- Characteristics of Patients and Treatment Recommendations from a Multidisciplinary Spinal Tumor Program.Palliative medicine reports · 2020Article
- Surgery as a Potential Treatment Option for Patients With Stage III Small-Cell Lung Cancer: A Propensity Score Matching Analysis.Frontiers in oncology · 2019Article
- MicroRNA-26b suppresses tumorigenicity and promotes apoptosis in small cell lung cancer cells by targeting myeloid cell leukemia 1 protein.The Kaohsiung journal of medical sciences · 2018Article
- Targeting chaperonin containing TCP1 (CCT) as a molecular therapeutic for small cell lung cancer.Oncotarget · 2017Article
- Bevacizumab in small cell lung cancer.Annals of translational medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small cell lung cancer (SCLC) is a very aggressive malignancy characterized by high cellular proliferation and early metastatic spread. In fact, although SCLC is a chemosensitive and radiosensitive disease, the initial responsiveness to chemotherapy is usually followed by development of resistance and the prognosis remains poor with a median survival of less than 12 months in patients with extensive disease (ED-SCLC). Furthermore, no significant progress has been made over the last years, with no newly approved drug. For all these reasons, SCLC represents for the oncologists a major challenge and an exciting field of clinical research. In this review, we analyze the most promising advances in development for SCLC with a special focus on antiangiogenic treatments, immunotherapy, novel chemotherapeutic and targeted agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.